New Advances in Liquid Biopsy to Increase BioMark's Assay Performance

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

(TheNewswire)



  

Vancouver, British Columbia – TheNewswire - August 13th, 2019 – BioMark Diagnostics Inc. (“BioMark”) (CNSX:BUX.CN) (FSE:20B) (OTCMKTS:BMKDF) is pleased to announce that the article “Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study” has been published in the peer-reviewed journal Cancers.

 

Rashid Ahmed, President and CEO, says, “This latest publication demonstrates our ability to engage an international team consisting of leading clinicians, scientists, researchers and data scientists in discovery and translational research for the development of a lung cancer diagnostic assay. The cross disciplinary team conducted a successful pilot study that provides evidence that its SSAT-1 (Spermidine Spermine Acetyl Transferase) assay signal is amplified, and the tissue specificity is increased by incorporating a panel of distinct metabolites.  When used in conjunction with the SSAT-1/polyamine pathway, these metabolites may provide the specificity required for diagnosing lung cancer from other cancer types and could be used as a promising lung diagnostic and treatment monitoring tool. We are excited about the possibility of increasing tissue specificity for other cancers by using specific metabolites to complement our SSAT-1 assay”.

The international team consisted of  Drs Christian Rolfo (Marlene and Stewart Greenebaum Comprehensive Cancer Centre, University of Maryland, School of Medicine Baltimore), Parveen Shahida Akhtar(Department of Medical Oncology, National Institute of Cancer Research & Hospital,  Dhaka, Bangladesh , Dr. Andrew Maksymiuk (CancerCare Manitoba),  Daniel Sitar (Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba), Bram Ramjiawan (Asper Clinical Research Institute & Office of Clinical Research, St. Boniface Hospital, Winnipeg, Manitoba), Paramjit Tappia (Asper Clinical Research Institute & Office of Clinical Research, St. Boniface Hospital, Winnipeg, Manitoba), Sandeep Singhal (Columbia University Medical Center, New York ) and Alessandro Russo (Medical Oncology Unit A.O. Papardo & Department of Human Pathology, University of Messina).

 

The paper is available through : https://www.mdpi.com/2072-6694/11/8/1069 and or at https://www.ncbi.nlm.nih.gov/pubmed/31362354

      

About Cancers

Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes article types including Research Papers, Reviews, Editorials, Communications, etc. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. The full experimental details must be provided so that the results can be reproduced.

There is, in addition, a unique feature of this journal: we accept studies showing meaningful but negative results. While there are many journals that focus on cancer studies, none of them actively accepts negative results. As a result, most negative data end up not being in the public domain even if the data were meaningfully negative and the study well designed. By accepting those negative results, our journal encourages scientists to share those data so that they would not need to repeat the experiments that somebody else has already done.

Scope of Journal

We publish high-quality articles including basic, translational, and clinical studies on all tumor types (https://medlineplus.gov/cancers.html).

About BioMark Diagnostics Inc.

 

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

 

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website https://thecse.com/.

  

For further information on BioMark, please Contact:

Rashid Ahmed Bux

President & CEO

BioMark Diagnostics Inc.

Tel. 604-370-0779

Email: info@biomarkdiagnostics.com  

        

Forward-Looking Information:

 

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Biomark.  Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

 

The CSE has not reviewed, approved or disapproved the content of this press release.

 

Copyright (c) 2019 TheNewswire - All rights reserved.